Pfizer PFE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $62.58B-1.6% | $63.63B+6.8% | $59.55B-41.1% | $101.18B+24.5% | ||
| $16.07B-10.0% | $17.85B-28.5% | $24.96B-27.3% | $34.34B+11.4% | ||
| $46.51B+1.6% | $45.78B+32.3% | $34.6B-48.2% | $66.83B+32.4% | ||
| 74.3%+2.4pp | 71.9%+13.8pp | 58.1%-8.0pp | 66.1%+4.0pp | ||
| $13.79B-6.4% | $14.73B-0.3% | $14.77B+8.0% | $13.68B+7.7% | ||
| $4.88B-14.7% | $5.71B+11.7% | $5.12B+18.6% | $4.32B+11.9% | ||
| —— | $8.03B— | —— | $34.73B+42.9% | ||
| -$266M-850% | -$28M+97.5% | -$1.12B-134% | $3.33B+79.7% | ||
| —— | $8.03B— | —— | $31.37B+42.7% | ||
| $25M+127% | $11M+173% | -$15M-350% | $6M+101% | ||
| —— | $1.41— | —— | $5.48+42.7% | ||
| —— | $1.42— | —— | $5.59+43.0% | ||
| 22.8B+0.2% | 22.8B0.0% | 22.8B-0.5% | 22.9B+0.6% | ||
| 22.7B+0.3% | 22.7B+0.4% | 22.6B+0.6% | 22.4B+0.1% | ||
| $9.27B+10.5% | $8.39B+10.6% | $7.58B-11.2% | $8.54B+11.6% | ||
| $4.88B-7.8% | $5.29B+11.7% | $4.73B+31.1% | $3.61B-2.4% | ||
| $1.55B-35.9% | $2.42B-17.8% | $2.94B+114% | $1.38B+71.4% | ||
| $4.69B+30.0% | $3.61B+14.6% | $3.15B-60.0% | $7.87B+5.9% | ||
| —— | $1.42— | —— | $5.59+40.1% | ||
| —— | $1.42— | —— | $5.48+39.4% | ||
| $0.00— | $0.00— | $0.00-100% | $0.01+113% | ||
| -$2.13B-1.5% | -$2.1B+38.9% | -$3.44B+10.0% | -$3.83B+10.9% | ||
| $4.69B+30.0% | $3.61B+14.6% | $3.15B-60.0% | $7.87B+5.9% | ||
| $2.74B-15.1% | $3.23B+45.7% | $2.22B+53.6% | $1.44B-1.7% | ||
| —— | $178M— | —— | $54M— | ||
| -$10.9B+36.4% | -$17.14B— | —— | —— | ||
| -$1.35B— | —— | -$33.17B-110% | -$15.78B+30.0% | ||
| $12.29B-3.6% | $12.74B— | —— | $29.27B-10.2% | ||
| $470M-79.2% | $2.26B-35.3% | $3.49B— | —— | ||
| -$6.72B-53.2% | -$4.39B— | —— | -$1.06B-122% | ||
| —— | -$2M— | —— | $200M— | ||
| —— | —— | -$5.17B— | —— | ||
| $2.63B-9.6% | $2.91B-25.5% | $3.91B+20.7% | $3.24B+19.4% | ||
| $14.36B+41.7% | $10.13B-67.3% | $30.97B-14.9% | $36.38B-5.4% | ||
| -$458M+2.3% | -$469M+25.7% | -$631M— | —— | ||
| —— | —— | $3.37B+1,616% | -$222M-131% | ||
| $1.1B-30.3% | $1.57B-20.7% | $1.98B+209% | $641M-1.2% | ||
| —— | —— | $0— | $0— | ||
| —— | $11.23B+374,100% | $3M-99.9% | $3.89B— | ||
| $10.44B-3.6% | $10.82B+1.3% | $10.68B-6.5% | $11.43B+10.3% | ||
| $799M-8.9% | $877M+67.0% | $525M-39.8% | $872M-26.2% | ||
| $9.77B+2.7% | $9.51B+2.9% | $9.25B+2.9% | $8.98B+2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pfizer's revenue?
- Pfizer (PFE) generated $63.3B in revenue over the trailing twelve months, up 1.4% year over year.
- Is Pfizer profitable?
- Pfizer reported $12.1B in net income over the trailing twelve months, a 15.7% net margin.
- What is Pfizer's earnings per share?
- Pfizer's diluted EPS over the trailing twelve months is $2.12.
- Where does Pfizer's income statement data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
